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MAGDALENA SIDHARTANI 
Dept. of Child Health
Faculty of Medicine Diponegoro University
Review PNAA 2004 and GINA 2009
PNAA 2004
Infrequent  episodic asthma
Frequent episodic asthma
Persistent asthma
Terminology Severity of asthma
Intermittent
Mild persistent
Moderate persistent
Severe persistent
GINA 2009
Controlled
Partly controlled
Uncontrolled
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Levels of asthma control
Characteristic Controlled Partly controlled uncontrolled
Daytime 
symptoms
Twice or 
less/week
More than 
twice/week
Three or more 
features of 
party 
controlled 
asthma present 
in any week
Limitation of 
activities
None Any  
Nocturnal 
symptoms/ 
awakening
None Any
Need for reliever/ 
rescue 
treatment
Twice or 
less/week
More than 
twice/week
Lung function 
(PEF or 
FEV1)
Normal < 80% predicted 
or personal 
best (if 
known)
Asthma
 Episodic disease
 Dynamic chronic illness
 Variability overtime
 Imperfect overlap between symptoms frequency and lung 
function
 Adding lung function measurement  change severity 
classification  change treatment
 Needs review and regular monitoring
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Peak expiratory flow (PEF)
 Inexpensive
 Patients can use at home
 May be helpful for patients with severe disease to monitor 
their change from baseline every day
 Not recommended for all patients with mild or moderate 
disease to use every day at home
 Effort and technique dependent
 Should not be used to make diagnosis of asthma
Lung Function Measurement
Spirometry
 Recommended to do spirometry pre- and post- use 
of an albuterol MDI to assess reversibility of airflow 
obstruction
 > 12% reversibility / increase FEV1 of 200cc is 
significant
 Obstructive pattern:  reduced FEV1/FVC ratio
 Restrictive pattern:  reduced FVC with a normal 
FEV1/FVC ratio
Lung Function Measurement
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Spirometry
 To identify reversible airway obstruction due to 
triggers
 To diagnose Exercise-induced asthma (EIA) or 
Exercise-induced bronchospasm (EIB) by measuring 
FEV1/FVC before and after exercise, then for 5-10 
minute intervals over 20-30 minutes looking for 
post-exercise bronchoconstriction
Lung Function Measurement
Goals in Asthma Control
 Achieve and maintain control of symptoms
 Prevent asthma episodes or attacks
 Minimal use of reliever medication
 No emergency visits to doctors or hospitals
 Maintain normal activity levels, including exercise
 Maintain pulmonary function as close to normal as 
possible
 Minimal (or no) adverse effects from medicine
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Evolving asthma treatment options
1975
1980
1985
1990 1995
2000
Large use of 
short-acting
ß2-agonists
“Fear” of 
short-acting 
ß2-agonists
Single
inhaler therapy
ICS treatment 
introduced
1972
Adding 
LAßA to ICS therapy
Kips et al, AJRCCM 2000 Pauwels 
et al, NEJM 1997 Greening et al, 
Lancet 1992
Bronchospasm Inflammation Remodelling
Asthma medications:
Controller
• to control / prevent symptoms &/ attack
• long term use 
• anti-inflammations
• inhaled steroid, ALTR, SRT, LABA, oral steroid
• Inhalation, oral
Reliever
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 Corticosteroids, inhaled
 budesonide
 Fluticasone
 The most effective anti-inflammatory medications
 Improve lung function
 Decrease airway hyper-responsiveness
 Reduce symptoms
 Decrease frequency and severity of  exacerbations
 Improve Quality of  Life (QoL)
Corticosteroids
 Inhaled Corticosteroids
 Anti-inflammatory (but precise MOA not known)
 Act locally in lungs 
 Some systemic absorption
 Risks of possible growth retardation outweighed by 
benefits of controlling asthma
 Not intended to be used as rescue medication
 Efficacy takes 1-2 weeks
 Preferred treatment in persistent asthma
Corticosteroids
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Corticosteroids
MDI with spacer
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Risk-benefit ratio of steroid
Benefit
Steroid
dose
Side-effects
Long-Acting Beta2-Agonists (LABA)
 Beta2-receptors are the predominant receptors in 
bronchial smooth muscle
 Stimulate ATP-cAMP  relaxation of bronchial 
smooth muscle and inhibition of release of 
mediators of immediate hypersensitivity
 Inhibits release of mast cell mediators such as 
histamine, leukotrienes, and prostaglandin-D2
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 Salmeterol (Serevent)
 Salmeterol with fluticasone (Advair)
 Should only be used as an additional treatment
when patients are not adequately controlled with ICS
 Should not be used as rescue medication
 Can be used >4 yrs with a DPI
 Deaths associated with inappropriate use as only 
medication for asthma
Long-Acting Beta2-Agonists (LABA)
Inhaled Steroid + LABA
Adding LABA to BUD:
 Reduces rate of mild exacerbations
 Reduces rate of severe exacerbations
 Improves FEV1
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ICS + LABA
Which LABA ?
Formoterol:
 Immediate relief (as fast as salbutamol)
 12 hours effect
 Can be combined with budesonide
 Formoterol 4.5 ug + Budesonide 100 ug
Salmeterol:
 Salmeterol 50 ug + Fluticasone propionate 100 ug or 
250 ug
Formoterol + Budesonide combination
the ‘flexible’ preventer
A
st
h
m
a 
si
g
n
s
Time
2x2 2x2 1x1
1x21x2
Quickly
gains control
Maintains
control
Asthma
worsening
Maintains
control
Reduce to
lowest 
adequate
dose that 
maintains
control
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Leukotriene receptor antagonists
 Leukotriene-mediated effects include:
 Airway edema
 Smooth muscle contraction
 Altered cellular activity associated with the inflammatory 
process
 Receptors in airway smooth muscle cells and 
macrophages and on other pro-inflammatory cells 
(including eosinophils and myeloid stem cells) and 
nasal mucosa
Leukotriene receptor antagonists
 No good long-term studies in pediatrics
 Montelukast as young as 2 yr dose 1 x 4 –5 mg; 
zarfirlukast age 7 yr dose 2 x 10 mg
 Alternate, but not preferred medication in persistent 
asthma and as addition to ICS
 Showed a statistically significant, but modest 
improvement when used as primary medication
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Leukotriene
Theophylline
 Narrow therapeutic index, maintain 5-20 mcg/mL
 Sustained release Theophylline (SRT) 5- 10 mcg/mL
 Variability in clearance leads to reach a therapeutic dose
 Mechanism of action
 Smooth muscle relaxation (bronchodilation)
 Suppression of the response of the airways to stimuli
 Increase force of contraction of diaphragmatic muscles
 Interacts with many other drugs
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Mast cell stabilizers
(cromolyn/nedocromil)
 Inhibits release of mediators from mast cells 
(degranulation) after specific antigens exposure
 Blocks Ca2+ ions from entering the mast cell
 Safe for pediatrics (including infants)
 Should be started 2-4 weeks before allergy season
 Can be used before exercise (not as good as ICS)
 Alternate th/ for persistent asthma
CONTROLLERS
Corticosteroids
Prednisolone, Betamethasone
Beclomethasone, Budesonide    
Fluticasone
Combinations
Salmeterol/Fluticasone
Formoterol/Budesonide
Salbutamol/Beclomethasone
Mast Cell Stabilisers
Sodium Cromoglycate
Anti-leukotrienes
Montelukast, Zafirlukast
Xanthines
SR Theophylline
Long acting β2 agonists
Salmeterol
Formoterol
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Low dose steroid
Medium dose 
steroid
Low dose 
steroid + LABA
Low dose 
steroid + ALTR
Low dose 
steroid +TSR
High dose 
steroid
Medium dose 
steroid + LABA
Medium dose 
steroid + ALTR
Medium dose 
steroid + TSR
ORAL STEROID
Longterm asthma management
UKK RESPIROLOGI
GINA updated 2009
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Step down
Wheeze free and well for three 
months:
 Oral steroid 
1 mg/kgBW/month, then
 SRT 
 Inhaled steroid: 50- 100ug/2-4 
weeks
lung function 
monitoring
Interrelated Asthma Management
1. Guided self-management education & 
communication
 Written
 Problem review
 Coordination & support
2. Asses & monitor asthma (PEFR)
3. Environmental control measures
4. Medication plan (accommodate variability 
among & within patients)
5. Plan for acute management
6. Regular follow-up care
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5 R’s  EDUCATION
1. Reach agreement of goals
2. Rehearse skills
3. Repeat messages
4. Reinforce 
5. Review
( Taggart, 2001)
THANK
YOU....
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